These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 29741774)

  • 1. Management of post-transplant lymphoproliferative disorders.
    DeStefano CB; Desai SH; Shenoy AG; Catlett JP
    Br J Haematol; 2018 Aug; 182(3):330-343. PubMed ID: 29741774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients.
    Preiksaitis JK
    Clin Infect Dis; 2004 Oct; 39(7):1016-23. PubMed ID: 15472855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of post-transplant Epstein-Barr virus-related lymphoproliferative disease in solid organ and hematopoietic stem cell recipients.
    Marques HH; Shikanai-Yasuda MA; dAzevedo LS; Caiaffa-Filho HH; Pierrotti LC; Aquino MZ; Lopes MH; Maluf NZ; Campos SV; Costa SF
    Rev Soc Bras Med Trop; 2014; 47(5):543-6. PubMed ID: 25467252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
    Lim WH; Russ GR; Coates PT
    Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-transplant lymphoproliferative disorders.
    Singavi AK; Harrington AM; Fenske TS
    Cancer Treat Res; 2015; 165():305-27. PubMed ID: 25655616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
    Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
    Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-Transplantation Lymphoproliferative Disorders in Adults.
    Dierickx D; Habermann TM
    N Engl J Med; 2018 Feb; 378(6):549-562. PubMed ID: 29414277
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of post-transplant lymphoproliferative disorders.
    Llaurador G; McLaughlin L; Wistinghausen B
    Curr Opin Pediatr; 2017 Feb; 29(1):34-40. PubMed ID: 27906865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients.
    San-Juan R; Comoli P; Caillard S; Moulin B; Hirsch HH; Meylan P;
    Clin Microbiol Infect; 2014 Sep; 20 Suppl 7():109-18. PubMed ID: 24475976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-Transplant Lymphoproliferative Disorders.
    Dharnidharka VR; Ruzinova MB; Marks LJ
    Semin Nephrol; 2024 Jan; 44(1):151503. PubMed ID: 38519279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphoma: risk and response after solid organ transplant.
    Jacobson CA; LaCasce AS
    Oncology (Williston Park); 2010 Sep; 24(10):936-44. PubMed ID: 21138175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-transplant lymphoproliferative disorders following solid-organ transplantation.
    Blaes AH; Morrison VA
    Expert Rev Hematol; 2010 Feb; 3(1):35-44. PubMed ID: 21082932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia.
    Weintraub L; Weiner C; Miloh T; Tomaino J; Joashi U; Benchimol C; Strauchen J; Roth M; Wistinghausen B
    J Pediatr Hematol Oncol; 2014 Nov; 36(8):e481-6. PubMed ID: 24878618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New approaches to posttransplant lymphoproliferative disorder (PTLD).
    Porcu P
    Clin Adv Hematol Oncol; 2005 Jan; 3(1):24-6. PubMed ID: 16166963
    [No Abstract]   [Full Text] [Related]  

  • 15. Post-transplant lymphoproliferative disease (PTLD): Pharmacological, virological and other determinants.
    Stojanova J; Caillard S; Rousseau A; Marquet P
    Pharmacol Res; 2011 Jan; 63(1):1-7. PubMed ID: 21056103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation.
    Green M
    Am J Transplant; 2001 Jul; 1(2):103-8. PubMed ID: 12099356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
    Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S; Zafar MN; Best J; Reddy HK
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients.
    Wistinghausen B; Gross TG; Bollard C
    Pediatr Hematol Oncol; 2013 Sep; 30(6):520-31. PubMed ID: 23802715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased MYC expression without MYC gene translocation in patients with the diffuse large B-cell-lymphoma subtype of iatrogenic immunodeficiency-associated lymphoproliferative disorders.
    Kabasawa N; Shiozawa E; Murai S; Homma M; Uesugi Y; Matsui T; Nakata A; Shimada S; Sasaki Y; Baba Y; Watanuki M; Arai N; Fujiwara S; Kawaguchi Y; Tsukamoto H; Uto Y; Yanagisawa K; Hattori N; Sakai H; Harada H; Nakamaki T; Takimoto M; Yamochi-Onizuka T
    J Clin Exp Hematop; 2021; 61(3):120-125. PubMed ID: 34511544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.